Marc Van den Eynde

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, Bernhard Mlecnik, Florence Marliot et al. · The Lancet · 2018 · 2.1K citations

Medicine, Immunology, Oncology +17

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

Evolution of Metastases in Space and Time under Immune Selection

Mihaela Angelova, Bernhard Mlecnik, Angela Vasaturo et al. · Cell · 2018 · 471 citations · Full text

Medicine, Biology, Immunology +12

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients

Marc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea et al. · Cancer Cell · 2018 · 288 citations · Full text

Medicine, Immunology, Oncology +14

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13